Primo 100 is a dihydrotestosterone derived anabolic steroid. Primo 100 contains methenolone enanthate, a long-acting methenolone ester producing a rapid onset of serum methenolone with a continued duration of action of 5 to 7 days after IM injection. Primo 100 is moderately anabolic with limited androgenic properties. Methenolone cannot aromatize to estrogen, reducing estrogenic side effects, and has a favorable safety profile among anabolic agents.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of these drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH). Methenolone is a dihydrotestosterone derivative which cannot be aromatized to estrogen and which acts upon the androgen receptor stimulating anabolism through increased nitrogen retention and protein synthesis in muscle tissue. Methenolone enanthate in a single dose pharmacokinetic study has demonstrated a mean elimination half-life of 6 days.
As an alternate or adjunctive therapy in patients for the promotion of weight gain following weight loss and/or muscular atrophy associated with extensive surgery, chronic infections, long term hospitalization, or severe trauma. To compensate for protein catabolism consequent to corticosteroid therapy.
DOSAGE AND ADMINISTRATION
Adult male: 100 - 200mg injected IM every 3 - 5 days for a duration of 8 to 12 weeks.
Male: Gynecomastia, increased frequency of erections, azospermia, priapism, oligospermia, prostatic hypertrophy,increased risk of prostate carcinoma.
Skin and Appendages: Hirsutism, pattern baldness and acne, gynecomastia.
Fluid/Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anti-coagulant therapy.
Nervous System: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Metabolic: Reduced glucose tolerance and inhibition of gonadotrophin secretion.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, and potentiation of sleep apnea.
Patients with diagnosed or suspected carcinoma of the prostate, breast, or testis.
Patients with diagnosed or suspected female breast carcinoma with hypercalcemia as androgenic agents may increase osteolytic bone resorption.
Women who are pregnant or may become pregnant because of possible masculinization of the fetus.
Patients with nephrosis or the nephrotic phase of nephritis. Patients with hypercalcemia.
Hypersensitivity to this product or any of its ingredients.
Patients with pre-existing cardiac, renal, and/or hepatic disease.
Discontinue treatment upon signs of jaundicing or hepatotoxicity.
Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease.
Patients on oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage of insulin and other hypoglycemic drugs.
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests - AST/ALT
Prostatic specific antigen - PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol
Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits.
Oral hypoglycemic agents: may inhibit the metabolism of oral hypoglycemic agents which may require adjustment of dosage.
Anticoagulants: Patients on anticoagulants should be carefully monitored during anabolic steroid therapy as anabolic steroids may increase sensitivity to oral anticoagulants. Patients should be monitored regularly during anabolic steroid therapy, particularly during initiation and termination of therapy.
100mg/ml - 5 ampules of 1ml each.
Protect from light, store at 15-25oC.
PRODUCT AUTHENTICATION :
NEWS / EVENTS
Magnum Pharmaceuticals Authentication
Try our new method to quickly authenticate your product using the 2D barcode.
Click the respective link to download the QR Reader app for your phone.
Please Note : We do not sell or ship to the USA, Europe, Australia or any other locations where prohibited. All information contained within this website or in any literature provided is not a prescription to use. Please seek the advice of a physician specializing in Andrology before use.
Not affiliated with Magnum Pharma (USA), Magnum Pharmaceuticals Inc. (USA), Magnum Chemi-Tech Ltd., or Magnum Nutraceuticals (Asia) Pte Ltd.
Distributors must submit licensing, a company profile, and our completed distributor application for approval prior to ordering.